BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 37899452)

  • 21. The performance of
    Jiang Y; Wen B; Li C; Tian Y; Xiao Z; Xu K; Xing D; Yu Z; Huang J; Jia J; He Y
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2114-2126. PubMed ID: 36808001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential utility of [
    Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibroblast Activation Protein-Targeted PET/CT with
    Xu W; Cai J; Peng T; Meng T; Pang Y; Sun L; Wu H; Zhang J; Chen X; Chen H
    J Nucl Med; 2024 Jan; 65(1):40-51. PubMed ID: 37884330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A head-to-head comparison of
    Qin C; Liu F; Huang J; Ruan W; Liu Q; Gai Y; Hu F; Jiang D; Hu Y; Yang K; Lan X
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3228-3237. PubMed ID: 33609152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FAPI Compared with FDG PET/CT for Diagnosis of Primary and Metastatic Lung Cancer.
    Wei Y; Ma L; Li P; Lu J; Ren J; Yan S; Wu H; Yuan S; Fu Z; Yu J
    Radiology; 2023 Aug; 308(2):e222785. PubMed ID: 37552075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [
    Zheng J; Liu F; Lin K; Zhang L; Huang N; Zheng W; Zhang J; Yao S; Miao W
    Mol Imaging Biol; 2022 Dec; 24(6):973-985. PubMed ID: 35945360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Added Value of
    Gu B; Xu X; Zhang J; Ou X; Xia Z; Guan Q; Hu S; Yang Z; Song S
    J Nucl Med; 2022 Jun; 63(6):875-881. PubMed ID: 34593594
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical Utility of F-18 Labeled Fibroblast Activation Protein Inhibitor (FAPI) for Primary Staging in Lung Adenocarcinoma: a Prospective Study.
    Li Y; Lin X; Li Y; Lv J; Hou P; Liu S; Chen P; Wang M; Zhou C; Wang X
    Mol Imaging Biol; 2022 Apr; 24(2):309-320. PubMed ID: 34816283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the role of 18 F-fluorodeoxyglucose PET/computed tomography and 68 Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma.
    Güzel Y; Kömek H; Can C; Kaplan İ; Kepenek F; Ebinç S; Büyükdeniz MP; Gündoğan C; Oruç Z
    Nucl Med Commun; 2023 Jul; 44(7):631-639. PubMed ID: 37114422
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Wang H; Zhu W; Ren S; Kong Y; Huang Q; Zhao J; Guan Y; Jia H; Chen J; Lu L; Xie F; Qin L
    Front Oncol; 2021; 11():693640. PubMed ID: 34249748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 68 Ga-FAPI-04 PET/CT with 18 F-FDG PET/CT for diagnosis and staging of gastric and colorectal cancer.
    Wang B; Zhao X; Liu Y; Zhang Z; Chen X; Jing F; Chen X; Hua Y; Zhao J
    Nucl Med Commun; 2024 Jul; 45(7):612-621. PubMed ID: 38686487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of [
    Chen H; Pang Y; Wu J; Zhao L; Hao B; Wu J; Wei J; Wu S; Zhao L; Luo Z; Lin X; Xie C; Sun L; Lin Q; Wu H
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1820-1832. PubMed ID: 32222810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of 18 F-FDG PET/CT and 68 Ga-FAPI-04 PET/CT in patients with non-small cell lung cancer.
    Can C; Kepenek F; Kömek H; Gündoğan C; Kaplan İ; Taşdemir B; Güzel Y; Agüloğlu N; Karaoğlan H
    Nucl Med Commun; 2022 Oct; 43(10):1084-1091. PubMed ID: 35972340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First Clinical Experience With [68Ga]Ga-FAPI-46-PET/CT Versus [18F]F-FDG PET/CT for Nodal Staging in Cervical Cancer.
    Wegen S; Roth KS; Weindler J; Claus K; Linde P; Trommer M; Akuamoa-Boateng D; van Heek L; Baues C; Schömig-Markiefka B; Schomäcker K; Fischer T; Drzezga A; Kobe C; Köhler C; Marnitz S
    Clin Nucl Med; 2023 Feb; 48(2):150-155. PubMed ID: 36607364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [
    Li Y; Zhang Y; Guo Z; Hou P; Lv J; Ke M; Liu S; Li S; Yin W; He J; Wang X
    Cancer Imaging; 2024 Jun; 24(1):68. PubMed ID: 38831354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of
    Pang Y; Zhao L; Luo Z; Hao B; Wu H; Lin Q; Sun L; Chen H
    Radiology; 2021 Feb; 298(2):393-402. PubMed ID: 33258746
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Li X; Lu N; Lin L; Chen Y; Yang S; Wang H; Liu X; Wu C; Xue X; Su X; Bai X; Liang T
    J Nucl Med; 2024 Feb; 65(2):206-212. PubMed ID: 38176719
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Sahin E; Kus T; Aytekin A; Uzun E; Elboga U; Yilmaz L; Cayirli YB; Okuyan M; Cimen V; Cimen U
    J Nucl Med; 2024 Apr; 65(4):512-519. PubMed ID: 38485276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Baseline
    Wu M; Wang Y; Yang Q; Wang X; Yang X; Xing H; Sang X; Li X; Zhao H; Huo L
    J Nucl Med; 2023 Oct; 64(10):1532-1539. PubMed ID: 37500263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Head-to-head intra-individual comparison of biodistribution and tumor uptake of
    Giesel FL; Kratochwil C; Schlittenhardt J; Dendl K; Eiber M; Staudinger F; Kessler L; Fendler WP; Lindner T; Koerber SA; Cardinale J; Sennung D; Roehrich M; Debus J; Sathekge M; Haberkorn U; Calais J; Serfling S; Buck AL
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4377-4385. PubMed ID: 34137945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.